Document is current
Any future updates will be listed below
-
Authors
Bielecki, Piotr https://orcid.org/0000-0002-5609-1066
Riesenfeld, Samantha J. https://orcid.org/0000-0001-9144-021X
Hütter, Jan-Christian https://orcid.org/0000-0002-1219-4821
Torlai Triglia, Elena https://orcid.org/0000-0002-6059-0116
Kowalczyk, Monika S.
Ricardo-Gonzalez, Roberto R. https://orcid.org/0000-0002-6135-4035
Lian, Mi
Amezcua Vesely, Maria C.
Kroehling, Lina
Xu, Hao
Slyper, Michal
Muus, Christoph
Ludwig, Leif S. https://orcid.org/0000-0002-2916-2164
Christian, Elena
Tao, Liming
Kedaigle, Amanda J. https://orcid.org/0000-0001-6156-5046
Steach, Holly R. https://orcid.org/0000-0003-0018-3129
York, Autumn G.
Skadow, Mathias H.
Yaghoubi, Parastou
Dionne, Danielle https://orcid.org/0000-0002-8338-4323
Jarret, Abigail
McGee, Heather M.
Porter, Caroline B. M.
Licona-Limón, Paula
Bailis, Will https://orcid.org/0000-0001-9420-6250
Jackson, Ruaidhrí
Gagliani, Nicola
Gasteiger, Georg
Locksley, Richard M. https://orcid.org/0000-0002-5468-6867
Regev, Aviv https://orcid.org/0000-0003-3293-3158
Flavell, Richard A. https://orcid.org/0000-0003-4461-0778
- License Information
-
More Information
Article History
Received: 23 October 2018
Accepted: 24 December 2020
First Online: 3 February 2021
Competing interests
: R.A.F. is a scientific advisor to GlaxoSmithKline, and a shareholder and consultant for Zai Lab. A.R. is a founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas Therapeutics and until 31 August 2020 was an SAB member of Syros Pharmaceuticals, Neogene Therapeutics, Asimov and ThermoFisher Scientific. From 1 August 2020, A.R. has been an employee of Genentech, a member of the Roche Group. P.B. is an equity holder in Celsius Therapeutics. P.B., S.J.R., J.-C.H., E.T.T., M.S.K., A.R. and R.A.F. are co-inventors on US Patent Application No. 16/681,050 directed to methods and compositions for modulating innate lymphoid cell pathogenic effectors described in this study. All other authors declare no competing interests.
